A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial on the efficacy and safety of Batifiban injection in patients with ACS undergoing PCI
Latest Information Update: 18 Oct 2024
Price :
$35 *
At a glance
- Drugs Bevifibatide (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions; Therapeutic Use
- 07 Aug 2024 New trial record